Inicio>>Signaling Pathways>> Immunology/Inflammation>>Myelopeptide-2 (MP-2)

Myelopeptide-2 (MP-2) (Synonyms: H2N-Leu-Val-Val-Tyr-Pro-Trp-OH )

Catalog No.GP10114

Products are for research use only. Not for human use. We do not sell to patients.

Myelopeptide-2 (MP-2) Chemical Structure

Tamaño Precio Disponibilidad Cantidad
1mg
31,00 $
Disponible
5mg
89,00 $
Disponible
10mg
157,00 $
Disponible
25mg
207,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com

Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

Myelopeptide-2 (MP-2) (C41H57N7O8), with the sequence Leu-Val-Val-Tyr-Pro-Trp, is originally isolated from the supernatant of porcine bone marrow cell culture, and is able to restore the mitogen responsiveness of human T lymphocytes inhibited by conditioned medium from HL-60 leukemia cells or measles virus. The MP-2 recovery effect is connected with its influence on the CD3 and CD4 antigen expression on T lymphocytes. Research results also suggest that the MP-2 involvement in regulatory processes is directed to the maintenance of immune homeostasis. This peptide is perspective to be applied in antitumor and antivirus therapy.

References:
1. Mikhailova AA, Belevskaya RG, Kalyuzhnaya M, Fonina LA, Liashenko VA, Petrov RV. Myelopeptide-2 recovers interleukin-2 synthesis and interleukin-2 receptor expression in human T lymphocytes depressed by tumor products or measles virus.

Reseñas

Review for Myelopeptide-2 (MP-2)

Average Rating: 5 ★★★★★ (Based on Reviews and 30 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Myelopeptide-2 (MP-2)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.